mCRC Clinical Trial
Official title:
A Prospective, Open-lable, Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal cancer.
This trial is conducted in patients with the refractory metastatic colorectal cancer. Eligible patients are randomized into two arms at 1:1 ratio to receive Irinotecan-based regimen or Oxaliplatin-based regimen until progress of the disease, unacceptable toxicity or withdrawal of consent by the patient. Study evaluation time is until death of patient or a deadline set by the researchers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02547480 -
LifePearl-Iri Pharmacokinetic Study
|
N/A | |
Active, not recruiting |
NCT03563157 -
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05127759 -
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
|
Phase 2 | |
Not yet recruiting |
NCT05690035 -
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
|
Phase 2 |